thymosin alpha 1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Water is released, and the second o-quinone product is formed together with the restoration of the initial Cu(II)-Cu(II) state to complete the catalytic cycle. This proposed catalytic cycle is supported by the experimental observation that stoichiometric amounts of o-quinone form after catechol addition to the enzyme, even when dioxygen is absent. Furthermore, both the oxidized Cu(II)-Cu(II) state and the reduced Cu(I)-Cu(I) state were the two states identified by the crystal structure of Ipomoea batatas. The monodentate binding of catechol to the copper center was supported by the crystal structure of catechol oxidase bound with the bound-substrate analogue inhibitor phenylthiourea, which also binds to the copper center in a monodentate fashion. However, one issue with this catalytic cycle is that the charge of the active site changes during the catalytic cycle from +1 to +3. This necessitates the presence of nearby bases that can store the protons; however, the X-ray crystal structure does not indicate the presence of any such bases as the histidine residues are coordinated with the copper centers. Other catalytic cycles elucidated with DFT calculations and crystal structures have been proposed which maintain the same charge in the active site throughout the cycle and thus do not require nearby bases. However, certain intermediates in the proposed cycle are not consistent with experimental findings such as that stoichiometric amounts of o-quinone can form after catechol addition in the absence of oxygen.
The tree is an acceptable source of forage or fodder for animals, providing vital protein and other nutrients. It does well in the dry season and in drought, while providing life saving food for local livestock and animals. Cows, goats and sheep eat the pods and leaves. There seems to be evidence that Mimosa tenuiflora forage or fodder cause development defects to pregnant ruminants in Brazil. The tree is an important source of forage for bees, especially during the dry season and in the beginning of the wet season. Like most plants in the family Fabaceae, Mimosa tenuiflora fertilizes the soil via nitrogen fixing bacteria. The tree is useful in fighting soil erosion and for reforestation. Mimosa tenuiflora is a very good source of fuel wood and works very well for making posts, most likely because of its high tannin content (16%), which protects it from rot. Due to its high tannin content, the bark of the tree is widely used as a natural dye and in leather production. It is used to make bridges, buildings, fences, furniture and wheels. It is an excellent source of charcoal and at least one study has been done to see why this is the case. The healing properties of the tree make it useful in treating domestic animals. A solution of the leaves or bark can also be used for washing animals in the prevention of parasites. Because the tree keeps most of its leaves during the dry season, it is an important source of shade for animals and plants during that time.
The Laminin Protein Laminin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P19137 (Laminin subunit alpha-1) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P24043 (Laminin subunit alpha-2) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: O15230 (Laminin subunit alpha-5) at the PDBe-KB. "How I learned to love laminin". YouTube. Imperial College London. April 13, 2011. (lecture by Professor Erhard Hoheneseter)
In 1933 Hodgkin was awarded a research fellowship by Somerville College, and in 1934, she moved back to Oxford. She started teaching chemistry with her own lab equipment. The college appointed her its first fellow and tutor in chemistry in 1936, a post which she held until 1977. In the 1940s, one of her students was Margaret Roberts (later Margaret Thatcher) who, while Prime Minister, hung a portrait of Hodgkin in her office at Downing Street out of respect for her former teacher. Hodgkin was, however a life-long Labour Party supporter. In April 1953, together with Sydney Brenner, Jack Dunitz, Leslie Orgel, and Beryl M. Oughton, Hodgkin was one of the first people to travel from Oxford to Cambridge to see the model of the double helix structure of DNA, constructed by Francis Crick and James Watson, which was based on data and technique acquired by Maurice Wilkins and Rosalind Franklin. According to the late Dr Beryl Oughton (married name, Rimmer), they drove to Cambridge in two cars after Hodgkin announced that they were off to see the model of the structure of DNA. Hodgkin became a reader at Oxford in 1955 and she was given a fully modern laboratory the following year. In 1960, Hodgkin was appointed the Royal Society's Wolfson Research Professor, a position she held until 1970. This provided her salary, research expenses and research assistance to continue her work at the University of Oxford. She was a fellow of Wolfson College, Oxford, from 1977 to 1983.
Historically, patients of frontal lobotomy were, immediately following surgery, often stuporous and incontinent. Some developed an enormous appetite and gained considerable weight. Seizures were another common complication of surgery. Emphasis was put on the training of patients in the weeks and months following surgery. The purpose of the operation was to reduce the symptoms of mental disorders, and it was recognized that this was accomplished at the expense of a person's personality and intellect. British psychiatrist Maurice Partridge, who conducted a follow-up study of 300 patients, said the treatment achieved its effects by "reducing the complexity of psychic life". Following the operation, spontaneity, responsiveness, self-awareness, and self-control were reduced. Activity was replaced by inertia, and people were mostly left emotionally blunted and restricted in their intellectual range. The consequences of the operation have been described as "mixed". However, many lobotomy patients suffered devastating postoperative complications, including intracranial hemorrhage, epilepsy, alterations in affect and personality, brain abscess, dementia, and death. Ominous portrayals of lobotomized patients in novels, plays, and films further diminished public opinion, and the development of antipsychotic medications led to a rapid decline in lobotomy's popularity and Walter Freeman's reputation. Others could leave the hospital or become more manageable within the hospital.
Sources: en.wikipedia.org
Blood flows back to the heart in the systemic deep veins, with the flow of blood maintained by one-way valves in the deep veins, superficial veins, and in the perforator veins. The venous valves serve to prevent regurgitation (backflow) due to the low pressure of veins, and the pull of gravity. They also serve to prevent the over-widening of the vein. A venous valve is bicuspid (having two leaflets) and is formed by an infolding of part of the tunica intima on either side of the lumen of the veins. The leaflets are strengthened with collagen and elastic fibres, and covered with endothelium. The endothelial cells on the surfaces of the leaflets facing the vein wall, are arranged transversely. On the leaflet surfaces that open to let the blood flow, the cells are arranged longitudinally in the direction of the flow. The leaflets are attached to the venous wall at their convex edges. Their margins are concave and are directed with the flow lying against the wall. As the valve forms, the vein wall where the leaflets attach, becomes dilated on each side. These widenings form the pockets, hollow cup-shaped regions, on the cardial side, known as the valvular sinuses. The endothelial cells in the sinuses are able to stretch twice as much as those in areas without valves. When the blood tries to reverse its direction (due to low venous pressure and the pull of gravity), the sinuses fill first closing the leaflets and keeping them together. Approximately 95% of the venous valves are in the small veins of less than 300 micrometres.
== Organisms and discovery == Creatinase was first identified by Roche, Lacombe, & Girard in 1950 in Pseudomonas eisenbergii and P. ovalis. It is produced by other bacterial genera including Bacillus, Flavobacterium, Micrococcus, Alcaligenes, Clostridium, Arthrobacter, and Paracoccus, and is produced by other species of Pseudomonas as well. In P. putida, creatinase is coded for by the creA gene and enables growth on creatine as the sole nitrogen source. Expression of creA is regulated by CahR, an AraC/GAT-R regulator that activates gene expression in the presence of creatine. This gene has also been cloned into Escherichia coli.
=== I2 receptor === The I2 receptor binding sites have been defined as being selective binding sites inhibited by the antagonist idazoxan that are not blocked by catecholamines. The major binding site is located on the outer mitochondrial membrane, and is proposed to be an allosteric site on monoamine oxidase, while another binding site has been found to be brain creatine kinase. Other known binding sites have yet to be characterized as of 2017. Preliminary research in rodents suggests that I2 receptor agonists may be effective in chronic, but not acute pain, including fibromyalgia. I2 receptor activation has also been shown to decrease body temperature, potentially mediating neuroprotective effects seen in rats. The only known antagonist for the receptor is idazoxan, which is non-selective.
==== Alleged and observed psychological disorders ==== Penis panic (koro in Malaysian/Indonesian) — delusion of shrinkage of the penis and retraction into the body. This appears to be culturally conditioned and largely limited to Ghana, Sudan, China, Japan, Southeast Asia, and West Africa. In April 2008, Kinshasa, Democratic Republic of Congo, the West African police arrested 14 suspected victims (of penis snatching) and sorcerers accused of using black magic or witchcraft to steal (make disappear) or shrink men's penises to extort cash for cure, amid a wave of panic. Arrests were made in an effort to avoid bloodshed seen in Ghana a decade before, when 12 penis snatchers were beaten to death by mobs. Penis envy — the contested Freudian belief of all women inherently envying men for having penises.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.